CCM
TEVA icon

Coldstream Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Coldstream Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Buy
14,474
+999
+7% +$33.3K 0.01% 743
2026
Q1 		$406K Buy
+13,475
New +$434K 0.01% 812
2025
Q2 		– Sell
-3,180
Closed -$48.9K – 3133
2025
Q1 		$48.9K Buy
+3,180
New +$56.8K ﹤0.01% 1717

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Coldstream Capital Management's TEVA Position: Q2 2026 in Review

Coldstream Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 7.4% in Q2 2026, buying an estimated $33.3K and bringing the position to 14,474 shares worth $490K. The position accounts for 0.01% of the portfolio, ranked #743.

Coldstream Capital Management first reported a position in TEVA in Q1 2025 and has held it in 3 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Coldstream Capital Management held 14,474 shares of Teva Pharmaceuticals worth $490K as of Q2 2026.
  • Coldstream Capital Management bought 999 Teva Pharmaceuticals shares in Q2 2026, an estimated $33.3K.
  • Teva Pharmaceuticals made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #743 holding.
  • Coldstream Capital Management first reported a position in Teva Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.